"GMP-grade" on a peptide listing: what ICH Q7 covers and where GMP actually begins

Every other quality descriptor attached to a synthetic peptide resolves, eventually, into a measurement. Purity is a chromatographic ratio produced under stated conditions. Peptide content is an assay result traceable to a certified standard. Identity is a measured mass against a calculated one. Each can be argued about, but each has a method behind it and a number in front of it.

“GMP-grade” is different in kind. It is not a measurement of the material at all. It is a claim about the system that produced the material — the documentation, the organizational structure, the change control, the inspection history — and it has no analytical readout. Nothing that can be run on the contents of a vial will confirm or refute it. This makes it the one term on a typical product listing that a certificate of analysis is structurally incapable of substantiating, and it is worth understanding precisely why, along with where the boundary of “GMP” falls in a peptide synthesis specifically.

What ICH Q7 is, and what it is not

The reference document for active pharmaceutical ingredient manufacturing is ICH Q7, Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients. It reached final status in November 2000 and was adopted by FDA as guidance in September 2001 under the title Q7A; the same text forms Part II of the EU GMP guide. Its stated purpose is to help ensure that APIs meet the quality and purity standards they purport to possess.

Two structural facts about Q7 shape everything downstream. First, it addresses the drug substance rather than the finished product — the separate framework governing finished dosage forms is distinct, and an operation can be inside one and outside the other. Second, in form it is guidance, which is to say a statement of expectations rather than a regulation with its own penalty. That distinction is thinner in practice than it looks: the underlying statutory obligation to manufacture drugs under current good manufacturing practice is not optional, and Q7 is the standard investigators inspect API operations against. It is the operative definition of the term.

What Q7 describes is not a specification. It is a quality system: a quality unit organizationally independent of production, defined and approved manufacturing instructions, executed batch records, qualified equipment, validated processes, controlled changes, investigated deviations and out-of-specification results, qualified suppliers, retained samples, and a stability program supporting whatever retest date appears on the label. None of these are properties of a peptide. All of them are properties of a facility and an organization, evidenced by documents and inspections.

The line where GMP begins

Q7 does not apply to every step in a synthetic route, and this is the part most often lost when the term is used loosely. The guide includes a table mapping GMP application onto the stages of manufacture, and for chemical synthesis the boundary is drawn at a specific point: the introduction of the API starting material into the process. From that step forward, the full expectations apply, escalating as the process approaches the final isolated substance — through intermediates, purification, physical processing, packaging, storage, and distribution.

Steps preceding the starting material are not ungoverned, but they are governed differently. The expectation is an appropriate level of control suitable for producing that starting material, not the complete Q7 apparatus. The consequence is that “manufactured under GMP” is only meaningful once you know where the manufacturer placed the starting material, because that designation determines how much of the chemistry sits inside the boundary.

That designation is not the manufacturer’s unilateral choice in a regulated context. ICH Q11 addresses the selection and justification of starting materials, requiring that the choice be defended on the basis of impurity fate and purge — how impurities in the starting material behave through subsequent steps and what relationship they bear to impurities in the final substance. The designation is proposed in a regulatory filing and assessed during review. Absent a filing, there is no reviewed boundary, and the phrase loses its fixed referent: it can describe anything from a fully documented operation to one that applied controls at the final purification step alone.

Where the boundary falls in peptide synthesis

Peptides make this question unusually concrete, because the answer determines whether the chemistry that generates the characteristic impurity profile is inside or outside the line.

The European Medicines Agency’s guideline on the development and manufacture of synthetic peptides (EMA/CHMP/CVMP/QWP/367182/2025) is the first dedicated regulatory text on the subject. Published in draft in October 2023, consulted on through April 2024, it took effect on 1 June 2026 — recent enough that its expectations are still working through the industry. It applies ICH Q11 logic to peptides explicitly.

Its treatment of starting materials is the relevant part. Protected amino acid derivatives are acceptable starting materials, and short fragments — dipeptides and similar — may qualify where scientifically justified. A synthesis resin preloaded with the first residue of the sequence through its linker is also considered a starting material. The bare solid support is not, on the reasoning that it is not incorporated as a significant structural fragment into the final molecule.

Follow that through for a thirty-residue sequence made by solid-phase synthesis. If the protected amino acids and the preloaded resin are the starting materials, then essentially the entire chain assembly — every deprotection, coupling, capping, and wash cycle, the final cleavage, the scavenger chemistry, and the purification — falls inside the GMP boundary. That is precisely the chemistry that produces deletion and truncation sequences, and side-chain artifacts, and it is where racemization is introduced. For small molecules, the starting material is often a late-stage fragment and a great deal of the synthesis sits outside; for peptides, the boundary is drawn early and almost the entire process is inside it.

The guideline also specifies what the starting materials themselves must be controlled for. Amino acid derivatives are expected to carry attributes covering appearance, identification, related impurities, other impurities, and assay. Raw material impurity considerations extend to stereoisomers and unprotected amino acids, along with their own residual solvents and elemental impurities, plus a transmissible spongiform encephalopathy risk assessment for materials of potential animal origin. Applicants are expected to supply synthetic flowcharts for the starting materials and a criticality assessment of which of their impurities can propagate into the final substance — impurity control justified by batch data rather than by reference to threshold tables alone, a point that connects directly to how impurity thresholds are set for this class.

What a certificate can and cannot carry

Set the two things side by side. A certificate of analysis reports results: which method, which parameters, which lot, which numbers. A GMP claim asserts something about the system that generated those results. The two are close to orthogonal.

A certificate can be entirely accurate and issued by an operation with no quality unit, no batch records, and no change control. A certificate from a fully compliant operation looks broadly similar — same assays, same format, often the same instruments. The document does not encode the difference, and no additional analytical test added to it would. What would substantiate the claim is a different category of evidence: a named manufacturing site, a referenced batch record, registration or inspection status, a quality agreement, an audit report. Where none of that accompanies the phrase, “GMP-grade” is a marketing assertion in the strict sense — it may be true, but nothing in the accompanying paperwork bears on it.

It is worth separating this cleanly from “research use only,” which is sometimes read as a quality tier below GMP. It is not a tier at all. It is a restriction on intended use, not a statement about manufacturing standard, and the two are independent axes: material can be well made and use-restricted, or poorly made and use-restricted. The phrase carries a specific regulatory meaning in a narrow labeling context that does not extend to bulk chemicals, where it functions as a disclaimer rather than a grade.

Q7 itself acknowledges gradation, incidentally — it contains a distinct section for APIs used in clinical trials, where the principles apply with flexibility appropriate to material made before a process is fixed. That accommodation exists because the framework anticipates investigational manufacture. It anticipates no tier at all for material outside that pathway, which is another way of saying the vocabulary was not designed for the context in which it is now most freely used.

Reading the claim for what it is

The practical position is straightforward once the categories are separated. GMP describes a manufacturer’s quality system, bounded at a starting material designation that in a regulated context is justified in a filing and assessed on review. For synthetic peptides, current expectations put that boundary early — at protected amino acid derivatives and preloaded resin — which means nearly all of the chemistry determining the impurity profile sits inside it.

That makes the term informative when it comes attached to the evidence that defines it, and empty when it does not. What remains evaluable from a certificate is what was always evaluable there: the methods named, the parameters disclosed, the results reported, and whether the analytical methods were validated and the reference standards qualified. Those questions have documentary answers. Whether a quality unit exists somewhere upstream is not among them, and treating an unsupported three-word claim as though it were a measured attribute is a category error that no amount of chromatography will correct.

What ICH Q7 is, and what it is not

The line where GMP begins

Where the boundary falls in peptide synthesis

What a certificate can and cannot carry

Reading the claim for what it is

Further reading